Palvella Therapeutics (NASDAQ:PVLA) Director George Jenkins Sells 13,152 Shares of Company Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director George Jenkins sold 13,152 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $133.69, for a total transaction of $1,758,290.88. Following the completion of the sale, the director owned 146,964 shares of the company’s stock, valued at $19,647,617.16. This trade represents a 8.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Stock Down 4.6%

Shares of NASDAQ:PVLA opened at $122.58 on Thursday. The firm’s 50-day simple moving average is $146.74 and its 200-day simple moving average is $134.32. Palvella Therapeutics, Inc. has a fifty-two week low of $68.96 and a fifty-two week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities research analysts expect that Palvella Therapeutics, Inc. will post -6.40 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PVLA shares. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a research note on Wednesday, August 5th. Chardan Capital began coverage on Palvella Therapeutics in a report on Monday, September 21st. They issued a “buy” rating and a $240.00 price target for the company. HC Wainwright decreased their price target on Palvella Therapeutics from $270.00 to $246.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $207.43.

Hedge Funds Weigh In On Palvella Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. KBC Group NV purchased a new stake in shares of Palvella Therapeutics during the 1st quarter worth approximately $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $35,000. Archer Investment Corp purchased a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $69,000. Quantbot Technologies LP acquired a new position in Palvella Therapeutics during the second quarter worth $71,000. Finally, State of Wyoming acquired a new position in Palvella Therapeutics during the second quarter worth $134,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics News Roundup

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $246 price target. Despite lowering its earnings forecasts, the analyst’s target remains well above recent trading levels, indicating continued confidence in Palvella’s longer-term opportunity. HC Wainwright analyst coverage
• Neutral Sentiment: Management will participate in the Chardan 10th Annual Healthcare Conference on October 20. The fireside chat could provide updates on Palvella’s development programs for rare skin diseases and vascular anomalies, although no new clinical or regulatory information was announced. Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
• Negative Sentiment: HC Wainwright significantly reduced its projected earnings for 2027 through 2030. Estimates were cut to losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029, while the 2030 forecast was reduced to $5.82 from $19.10. The revisions suggest a slower path to profitability and likely contributed to the stock’s decline.
• Negative Sentiment: Director George Jenkins sold 20,326 shares worth approximately $2.69 million across October 12 and 13. The transactions reduced his direct ownership by roughly 13% overall. Both sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which may lessen their significance, but the sizable insider selling can still weigh on investor sentiment. Palvella Therapeutics SEC insider transaction filing

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.